跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NUVAXOVID - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NUVAXOVID
Authorized
STANDARD
NUVAXOVID
novavax inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
1fc85f954a51c608
Company
novavax inc.
Type
Standard
Approval Details
Approval Id
1fc85f954a51c608
Drug Approval Canada Name
NUVAXOVID
Product Name
NUVAXOVID
Status
Marketed
Status Date
2024-09-19
Original Market Date
2023-12-08
Din
02543656
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BN04 COVID-19, PROTEIN SUBUNIT
Atc Name
j 07 bn 04
Aig Number
0163400001
Company Name
novavax inc.
Company Address
700 Quince Orchard Road, Gaithersburg, Maryland, United States, 20878
Active Ingredients
SARS-COV-2 RECOMBINANT SPIKE PROTEIN
5 MCG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
1fc85f954a51c608
Type
Standard
Back to Health Canada Approvals